This inventor holds 2 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Gubra A/s. Active years: 2024-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2025
Title: Innovations of Søren Ljungberg Pedersen
Introduction
Søren Ljungberg Pedersen is a notable inventor based in Borup, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of receptor agonists. With a total of 2 patents, his work focuses on innovative solutions for medical conditions.
Latest Patents
One of his latest patents is related to soluble NPY2 receptor agonists. This invention involves PYY analogues that have alanine at position 4, lysine at position 7, QRY as the C-terminal end, and a half-life extending group. These analogues are designed to be soluble around pH 6 and 7. The invention also encompasses pharmaceutical compositions that include such PYY analogues and their medical applications.
Another significant patent by Pedersen involves HAManalogues with improved amylin receptor (hAMY3R) potency. This invention focuses on hAManalogues that exhibit enhanced potency at the hAMY3R receptor, with an EC value of ≤250 pM. These analogues are primarily based on the sequence of the human adrenomedullin fragment hAM. The invention also highlights the selectivity of these agonists for the amylin receptor and their potential use in treating conditions such as obesity, NASH, and diabetes.
Career Highlights
Throughout his career, Søren Ljungberg Pedersen has worked with prominent companies in the pharmaceutical industry, including Gubra A/S and Boehringer Ingelheim International GmbH. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Pedersen has collaborated with notable colleagues such as Jens Christian Frøslev Nielsen and Kristoffer Tobias Gustav Rigbolt. These partnerships have likely enhanced his research and development efforts in the pharmaceutical field.
Conclusion
Søren Ljungberg Pedersen is a distinguished inventor whose work in receptor agonists has the potential to impact the treatment of various medical conditions. His innovative patents and collaborations reflect his commitment to advancing pharmaceutical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile